Customer concentration
A few customers account for a large share of revenue, so renewals or project changes can materially affect results.
- Scope
- Moderna, VA MVP, Natera
- Materiality
- high
Personalis, Inc.
Personalis, Inc. develops and sells advanced cancer genomic testing services for precision oncology and research applications. The company serves physicians, pharmaceutical and biopharmaceutical companies, diagnostics firms, universities, non-profits, and government customers from its CLIA-certified, CAP-accredited laboratory in Fremont, California.
−112,0 %
22,7 %
−116,7 %
−17,7 %
6.76
6.76
| % | |
|---|---|
| Clinical diagnostic testing | 20% Tumor-informed and other cancer tests used by physicians to guide care and monitor recurrence. |
| Pharma tests and services | 45% Testing and analytics for pharmaceutical oncology programs, translational research, and clinical trials. |
| Enterprise sales | 15% Tumor profiling and diagnostic inputs sold to other businesses, including Natera-related services. |
| Population sequencing | 18% Large-scale sequencing services supporting population genetics and research initiatives. |
| Other research services | 2% Genomic tests and analytics sold to universities and non-profit research customers. |
Personalis sells to both clinical and research customers, with a large share of revenue tied to a small number of...
- Pharmaceutical and biopharmaceutical companiesprimary
They buy testing services and analytics for translational research, biomarker discovery, and clinical trials.
- Clinical diagnostics / physiciansprimary
They order NeXT Personal Dx and related cancer tests to detect residual or recurrent disease and support therapy selection.
- Diagnostics companiessecondary
They purchase whole exome sequencing and tumor analysis services as inputs to their own diagnostic offerings.
- Government and population sequencing programssecondary
They use whole genome sequencing and analytics for large-scale genetic research initiatives.
- Universities and non-profitsemerging
They buy genomic testing and analytics for academic and non-commercial research projects.
Personalis derives most of its revenue in the United States, with smaller contributions from Europe, including the U.K...
- •United States is the main revenue market and operating base
- •Europe, including the U.K., is a smaller but established market
- •Asia-Pacific and other regions contribute a limited share of revenue
- •Fremont, California houses the CLIA and CAP-accredited laboratory
- •Geographic sales coverage is organized through a small direct sales force
Personalis is focused on expanding adoption of its NeXT Personal testing platform in clinical diagnostics while...
01
Expand clinical diagnostics commercializationshort-term
Clinical adoption can create a broader, more recurring customer base than project-based research work.
02
Build reimbursement and clinical evidencemedium-term
Coverage and published evidence support physician adoption and payer reimbursement.
03
Diversify customer concentrationmedium-term
Reducing dependence on a few large customers lowers volatility from trial timing and renewals.
Personalis faces customer concentration risk because a small number of large accounts can drive a substantial share of...
Clinical trial and project timing
Pharma and research revenue depends on the start, pace, and completion of external studies.
- Scope
- Pharma tests and services
- Materiality
- high
Cybersecurity and sensitive data protection
The company processes PHI, genomic data, and financial information, increasing breach and compliance risk.
- Scope
- Laboratory and third-party systems
- Materiality
- high
Reimbursement and coverage risk
Clinical diagnostics depend on Medicare and private payer coverage for adoption and volume growth.
- Scope
- NeXT Personal Dx
- Materiality
- high
Sustained losses
The company has a history of losses and may need continued capital to support growth and operations.
- Scope
- Corporate liquidity and operating flexibility
- Materiality
- high
Revenue recognition
Can shift revenue between quarters and affect comparability
Leases
Affects right-of-use assets, lease liabilities, and expense timing
Common stock warrants
Can materially affect other income/expense and equity
Allowance for credit losses / collectability
Can affect bad debt expense and working capital
: 29.4.2026